Editas Medicine, Inc. (NASDAQ: EDIT) was upgraded by analysts at Evercore ISI from an "in-line" rating to an "outperform" rating.
Editas Medicine to Participate in Upcoming Investor Conferences
Growth Investors: Industry Analysts Just Upgraded Their Editas Medicine, Inc. (NASDAQ:EDIT) Revenue Forecasts By 19% [Yahoo! Finance]
Editas Medicine, Inc. (NASDAQ: EDIT) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.
Editas Q3 Loss Narrower Than Expected, Revenues Decrease Y/Y [Yahoo! Finance]